The Centre fr Research n Filariasis and ther Trpical Diseases (CRFilMT) Jseph KAMGNO
Plan Histry Presentatin Infrastructure Main research tpics Main achievements CANTAM Netwrk 2
Histry CRFilMT was created in 2005 with the main bjectives t: ensure the surveillance f pst-ivermectin Severe Adverse Events (SAEs) ensure the safe implementatin f Cmmunity Directed Treatment with ivermectin in La c-endemic areas fllwing the MEC/TCC guidelines cnduct research t identify the ther risk factrs, the pathphysilgy, the better management and the preventin f pst-ivermectin SAEs With years, CRFilMT has extended his activities t NTDs in general 3
Presentatin (1) CRFilMT Gvernment Bdies Administratin cuncil Scientific cmmittee Management bard 4
Presentatin (2) Staff (20 persnnel) Scientists (Epidemilgists, Parasitlgists, Immunlgists, Entmlgists) General practitiners Pharmacist Nurses Lab Technicians Administratin team Administratr Accuntants (2) 5
Infrastructure (1) Actual site Offices Meeting rm Labratries Insectary Mlluscarium 6
Infrastructure (2) Future site Clinical Research Centre Pre-clinical studies Phase I r II Clinical Trials (12 beds) Clinical Labratry Specialized Labratries Mlecular Bilgy Virlgy Bacterilgy Parasitlgy Amphitheater Meeting rm 7
Main Research Tpics Mapping f Filariasis in Camern and the Sub regin Mass treatment Impact studies Diagnstic tls evaluatin Pst Ivermectin SAEs Pre-clinical tests and Clinical trials Experimental studies n the transmissin f NTDs (Onging) 8
Mapping f filariasis and impact studies Natinwide Mapping f lymphatic filariasis in Camern Cntributin in nchcerciasis and liasis mapping in Camern and in the sub-regin Lymphatic Filariasis Transmissin Assessment Survey in Camern Onchcerciasis pst-treatment impact assessments and cllateral impact f CDTI n liasis 9
Diagnstic tls Evaluatin Evaluatin f newly designed RDT fr nchcerciasis, lymphatic filariasis and liasis diagnsis Ov16 (Onchcerciasis) Ov16 / Wb 123 Biplex (Onchcerciasis + lymphatic filariasis) FTS (Lymphatic Filariasis) La Antibdy Rapid Test (Liasis) Evaluatin and validatin f the LaScpe, the tls fr Test and Nt Treat Strategy 10
Severe Adverse Events (SAEs) Surveillance f pst-ivermectin (IVM) SAEs Other risk factrs f pst IVM SAEs Pathphysilgy f pst IVM SAEs Preventin f Pst IVM SAEs 11
Surveillance f pst IVM SAEs and Training Since 2000 t date, we have recrded all the SAEs in Camern These SAEs were reprted t the Ministry f Public Health and t Mectizan Dnatin Prgram Training f persnnel in Camern and in Africa abut the diagnsis and management f pst IVM SAEs 12
Others risk factrs f pst IVM SAEs Malaria was hypthesized as risk factr f pst-ivm SAE, but we fund n relatinship between infectin by malaria and pst IVM SAE. La strains was als cnsidered as a ptential risk factr f pst-ivm SAE with the hypthesis that L. la inducing SAEs had a ncturnal peridicity. A similar peridicity was bserved between cases f SAEs and cntrls. 13
Preventin f pst IVM SAEs Five clinical trials with the bjective t safely treat Liasis (Pre-treatment) Albendazle Lw dse ivermectin Antimalarial drugs Test and Nt Treat (TaNT) 14
Test and Nt Treat (TaNT) Systematic test f la micrfilaraemia befre the treatment with IVM Pilt Studies in 02 Health Districts in Camern (Okla and Sa) Mre than 55,000 treatments in La endemic areas withut a single pst-treatment SAE Extensin f this strategy in La endemic areas in Central Africa Crdinatrs f Onch prgram f the Sub-Regin and DRC will cme t Camern 15
Achievements Mre than 100 MD, Master and PhD theses ~100 Scientific Publicatins in peer reviewed Jurnals Natinal Recgnitin 2009: Ministry f Health Official Satisfactin Testimny Internatinal Recgnitin 2015: Islamic Bank f Develpment Price fr Science and Technlgy Netwrking 16
CANTAM Netwrk CANTAM is a Netwrk funded by EDCTP HIV TB Malaria Since 2017: NTDs Crdinatin f NTDs activities in the Netwrk by CRFilMT 17
Sme partners 18
Acknwledgements Thank Yu fr yur kind Attentin 19